NCT05642182

Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques

A Study of Improvement in Psoriasis Symptoms Associated with Combinations of Biologically Active Natural Substances (SFA-002) with Known Safety Profile

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 90 (estimated)
• Sponsor: SFA Therapeutics · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the safety, metabolism and potential effect of drug product SFA-002 on mild moderate and severe chronic plaque psoriasis. Psoriasis is a common chronic skin disorder that affects over 4 million people. There is no cure for psoriasis and treatment is directed at controlling patients' symptoms.

Detailed description

Up to ninety volunteers with mild to moderate chronic plaque psoriasis will be recruited for an open label 24 week prospective study of the safety of 2 different dosages for 12 weeks of active therapy and 12 weeks of follow up. Blood will be drawn to determine any clinical effect on each group at the 12 week time mark and residual effects after 24 weeks. Throughout the study the investigators will perform both clinical and laboratory assessments to measure safety and response.

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	SFA002	Study drug formula without excipient
DRUG	SFA002	Study Drug SFA002 with excipient (Propionate)

Timeline

• Start date: 2022-03-31
• Primary completion: 2025-07-30
• Completion: 2025-07-31
• First posted: 2022-12-08
• Last updated: 2025-01-09

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated drug study